Michael P. Nofi serves as Chief Financial Officer at Edgewise Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel treatments for muscle diseases. With over 20 years of experience in finance within the biotechnology and pharmaceutical industries, Nofi brings a proven track record of guiding companies through critical growth phases, including public offerings and strategic partnerships. He holds a Bachelor of Science in Accounting from Fairfield University and is a Certified Public Accountant (CPA). Prior to joining Edgewise in 2021, Nofi was CFO at Catabasis Pharmaceuticals, where he led the company's financial operations during its merger with Fortress Biotech and subsequent Nasdaq listing. His earlier roles included senior finance positions at Alexion Pharmaceuticals, Ironwood Pharmaceuticals, and Genzyme Corporation, where he managed budgeting, forecasting, investor relations, and compliance for late-stage clinical and commercial-stage programs. Notable achievements include orchestrating multiple debt and equity financings totaling over $500 million and optimizing financial strategies that supported pipeline advancements and operational efficiencies. At Edgewise Therapeutics, Nofi oversees all financial aspects, including capital raising, financial planning, and risk management, playing a pivotal role in the company's progression of investigational therapies like sevasemten and EDG-5506 through clinical trials. His strategic leadership has been instrumental in securing significant funding rounds and positioning Edgewise for long-term success in addressing unmet needs in muscle-related disorders.